Although both control and HRHF rats showed CCN2 expression in cells lining the bone and in marrow spaces, HRHF rats also showed increased deposition within the bone matrix.[7] A monoclonal anti‐CCN2 antibody, known as FG‐3019 or Pamrevlumab, is being developed for use in treating multiple diseases, including muscular dystrophy and idiopathic pulmonary fibrosis.[23, 24, 25] We obtained this antibody and applied it to our model. Here, CCN2 is linked to muscular dystrophy.